

# Kausik K Ray

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5825164/kausik-k-ray-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191  
papers

26,157  
citations

65  
h-index

161  
g-index

217  
ext. papers

35,580  
ext. citations

10  
avg, IF

6.74  
L-index

#	Paper	IF	Citations
191	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress.. <i>Biomarker Insights</i> , <b>2022</b> , 17, 11772719211066791	3.5	
190	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	1
189	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. <i>Lancet, The</i> , <b>2022</b> ,	40	4
188	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies.. <i>Archives of Medical Science</i> , <b>2022</b> , 18, 604-616	2.9	3
187	Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. <i>American Heart Journal</i> , <b>2022</b> , 243, 54-65	4.9	
186	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.. <i>Atherosclerosis</i> , <b>2021</b> , 343, 28-50	3.1	4
185	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	1
184	FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia. <i>Scientific Reports</i> , <b>2021</b> , 11, 20421	4.9	0
183	Familial Hypercholesterolemia: JACC Focus Seminar 4/4. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1831-1843	15.1	1
182	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 1279-1289	3.9	92
181	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1182-1193	15.1	31
180	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , <b>2021</b> , 320, 1-9	3.1	1
179	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , <b>2021</b> , 322, 77-81	3.1	5
178	TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. <i>Atherosclerosis</i> , <b>2021</b> , 322, 8-14	3.1	0
177	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , <b>2021</b> , 35, 853-864	3.9	16
176	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. <i>Atherosclerosis</i> , <b>2021</b> , 325, 46-56	3.1	5
175	Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 284-291	9.9	23

174	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 129-139	59.2	243
173	Coronary Artery Calcium to Improve the Efficiency of Randomized Controlled Trials in Primary Cardiovascular Prevention. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 1005-1016	8.4	11
172	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , <b>2021</b> , 235, 104-112	4.9	19
171	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , <b>2021</b> , 42, 1289-1367	9.5	920
170	Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 2168-2185	8.6	2
169	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	11
168	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , <b>2021</b> , 42, 3227-3337	9.5	358
167	Clinical implications and outcomes of the ORION Phase III trials. <i>Future Cardiology</i> , <b>2021</b> , 17, 769-777	1.3	6
166	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions : In Partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology. <i>Current</i>	4.2	
165	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	31
164	The power of lipid registries for cardiovascular disease prevention. <i>Current Opinion in Lipidology</i> , <b>2021</b> , 32, 342-348	4.4	0
163	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe [Methodology and rationale for the multinational observational SANTORINI study. <i>Atherosclerosis Plus</i> , <b>2021</b> , 43, 24-30		2
162	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , <b>2021</b> , 398, 1713-1725	4.0	14
161	Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 1	2.3	
160	Novel emerging therapies in atherosclerosis targeting lipid metabolism. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 611-622	5.9	16
159	Apabetalone - $\beta$ TET protein inhibition in cardiovascular disease and Type 2 diabetes. <i>Future Cardiology</i> , <b>2020</b> , 16, 385-395	1.3	2
158	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Circulation</i> , <b>2020</b> , 141, 1742-1759	16.7	117
157	Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 763-770	5.9	8

156	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1507-1519	59.2	302
155	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1520-1530	59.2	197
154	Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. <i>Current Opinion in Lipidology</i> , <b>2020</b> , 31, 182-186	4.4	7
153	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 1663-1674 <sup>3.9</sup>		1
152	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2020</b> , 27, 95-103	4	20
151	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 14	8.7	12
150	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , <b>2020</b> , 17, 360-377	14.8	41
149	Low Density Lipoprotein Cholesterol-Lowering Strategies and Population Health: Time to Move to a Cumulative Exposure Model. <i>Circulation</i> , <b>2020</b> , 141, 873-876	16.7	17
148	Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 228-232	8.5	0
147	The year in cardiology: cardiovascular prevention /The year in cardiology 2019. <i>Revista Romana De Cardiologie</i> , <b>2020</b> , 30, 20-29	0.1	
146	Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records. <i>JMIR Research Protocols</i> , <b>2020</b> , 9, e17548	2	
145	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , <b>2020</b> , 42, e6-e8	1.7	3
144	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGAM2015 study. <i>Atherosclerosis Supplements</i> , <b>2020</b> , 42, e15-e24 <sup>1.7</sup>		7
143	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , <b>2020</b> , 41, 2313-2330	9.5	301
142	Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?. <i>Current Opinion in Lipidology</i> , <b>2020</b> , 31, 111-118	4.4	8
141	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 217-229	16.2	85
140	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , <b>2020</b> , 41, 2304-2312	9.5	33
139	Inclisiran-New hope in the management of lipid disorders?. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 16-27 <sup>4.9</sup>		45

138	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 77-89	6.4	37
137	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , <b>2020</b> , 41, 1157-1163	9.5	12
136	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 4245-4255	9.5	44
135	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 649-659.e6	4.9	24
134	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1124-1135	16.2	46
133	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016506	6	4
132	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e018189	6	2
131	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 50-67	18.1	48
130	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 111-188	9.5	2236
129	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , <b>2019</b> , 394, 1169-1180	40	106
128	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1381-1391	27.4	79
127	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , <b>2019</b> , 290, 59-65	3.1	19
126	Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1067-1075	16.2	58
125	Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 364-373	27.4	263
124	Cholesterol-Lowering Agents. <i>Circulation Research</i> , <b>2019</b> , 124, 354-363	15.7	17
123	A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1101-1110	6.7	5
122	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 71	8.7	64
121	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , <b>2019</b> , 288, 194-202	3.1	35

120	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , <b>2019</b> , 286, 40-45	3.1	6
119	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21 Suppl 1, 6-16	6.7	7
118	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1022-1032	59.2	265
117	Mendelian Randomization Study of and Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1033-1042	59.2	116
116	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , <b>2019</b> , 394, 697-708	40	43
115	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. <i>Atherosclerosis</i> , <b>2019</b> , 288, 85-93	3.1	10
114	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2019</b> , 7, 618-628	18.1	120
113	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5253-5262	5.6	1
112	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 149	8.7	13
111	American Heart Association® Cholesterol CarePlan as a Smartphone-Delivered Web App for Patients Prescribed Cholesterol-Lowering Medication: Protocol for an Observational Feasibility Study. <i>JMIR Research Protocols</i> , <b>2019</b> , 8, e9017	2	2
110	Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk. <i>Acta Diabetologica</i> , <b>2019</b> , 56, 87-96	3.9	7
109	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 173-176	14.6	43
108	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , <b>2018</b> , 138, 770-781	16.7	65
107	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. <i>Heart</i> , <b>2018</b> , 104, 1699-1705	5.1	11
106	Inclisiran for the treatment of dyslipidemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 287-294	5.9	27
105	Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1337-1341	6.7	39
104	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1479-1489	6.7	63
103	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , <b>2018</b> , 15, 261-272	14.8	63



102	High risk-highest benefit strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. <i>European Heart Journal</i> , <b>2018</b> , 39, 2546-2550	9.5	53
101	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2018</b> , 4, 119-127	6.4	11
100	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , <b>2018</b> , 39, 2526-2539	9.5	156
99	Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2018</b> , 25, 422-429	4	16
98	Lipids and Lipoproteins in Risk Prediction. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 213-220	2.5	5
97	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , <b>2018</b> , 39, 2600-2601	9.5	9
96	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , <b>2018</b> , 39, 1131-1143	9.5	132
95	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 109-115	11.5	70
94	Effect of Serial Infusions of CER-001, a Pre-High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 815-822	16.2	87
93	Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. <i>Atherosclerosis</i> , <b>2018</b> , 275, 434-443	3.1	22
92	Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. <i>Circulation</i> , <b>2018</b> , 138, 1304-1316	16.7	84
91	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 1281-1288	3.3	134
90	Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. <i>Circulation</i> , <b>2018</b> , 137, 2413-2421	16.7	0
89	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. <i>Frontiers in Cardiovascular Medicine</i> , <b>2018</b> , 5, 199	5.4	20
88	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , <b>2018</b> , 39, 2540-2545	9.5	75
87	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. <i>Atherosclerosis</i> , <b>2018</b> , 277, 470-476	3.1	2
86	Epidemiology of familial hypercholesterolaemia: Community and clinical. <i>Atherosclerosis</i> , <b>2018</b> , 277, 289-297	3.1	19
85	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , <b>2018</b> , 277, 234-255	3.1	93

84	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2269-2279	4 <sup>0</sup>	46
83	Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009221	6	4
82	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1352-1358	3	18
81	Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. <i>BMJ Open</i> , <b>2017</b> , 7, e013255	3	23
80	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , <b>2017</b> , 38, 2459-2472	9.5	1267
79	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , <b>2017</b> , 261, 12-18	3.1	21
78	What imaging techniques should be used in primary versus secondary prevention for further risk stratification?. <i>Atherosclerosis Supplements</i> , <b>2017</b> , 26, 36-44	1.7	4
77	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. <i>Atherosclerosis</i> , <b>2017</b> , 263, 112-118	3.1	3
76	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. <i>BMJ Open</i> , <b>2017</b> , 7, e013851	3	18
75	PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?. <i>Heart</i> , <b>2017</b> , 103, 1670-1679	5.1	18
74	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , <b>2017</b> , 122, 105-117	10.2	16
73	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43, 453-459	5.4	12
72	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1430-1440	59.2	507
71	Prediction of cardiovascular risk in patients with familial hypercholesterolaemia. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2017</b> , 3, 274-280	4.6	16
70	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , <b>2017</b> , 75, 731-767	6.4	186
69	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , <b>2017</b> , 13, 965-1005	2.9	173
68	Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans. <i>Lipids in Health and Disease</i> , <b>2017</b> , 16, 192	4.4	34
67	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2017</b> , 7, 45-51	2.6	35



66	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1781-1792	6.7	84
65	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. <i>Circulation</i> , <b>2017</b> , 136, 1878-1891	16.7	92
64	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1451-1457	3.2	2
63	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 70	8.7	21
62	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 69-76	14.6	162
61	Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 364-374	6.7	16
60	The need for a new classification of cholesterol lowering therapies. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 67-69	2.5	
59	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 947-956	27.4	169
58	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1290-1301	15.1	133
57	Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. <i>Circulation</i> , <b>2016</b> , 134, 1931-1943	16.7	84
56	Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. <i>BMJ Open</i> , <b>2016</b> , 6, e011805	3	20
55	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 162-71	7	24
54	Where to now in cardiovascular disease prevention. <i>Atherosclerosis</i> , <b>2016</b> , 251, 483-489	3.1	2
53	Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , <b>2016</b> , 111, 163-179	10.2	17
52	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 850-61	18.1	215
51	Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 1696-709	3.5	53
50	The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 520-32	7	110
49	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , <b>2016</b> , 6, 19188	4.9	38

48	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , <b>2016</b> , 22, 1-32	1.7	60
47	Diabetic microvascular triopathy, smoking, and risk of cardiovascular events - Author@ reply. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 888-889	18.1	
46	Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 588-97	18.1	118
45	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. <i>Circulation</i> , <b>2016</b> , 134, 1419-1429	16.7	104
44	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , <b>2016</b> , 253, 194-208	3.1	117
43	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?. <i>Circulation</i> , <b>2015</b> , 132, 433-40	16.7	21
42	The evolving role of CETP inhibition: beyond HDL cholesterol. <i>Lancet, The</i> , <b>2015</b> , 386, 412-4	4.0	9
41	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , <b>2015</b> , 242, 87-96	3.1	37
40	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. <i>Atherosclerosis</i> , <b>2015</b> , 241, 409-18	3.1	63
39	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 935-55	4.1	94
38	Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. <i>Cardiology and Therapy</i> , <b>2015</b> , 4, 25-38	2.8	43
37	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , <b>2015</b> , 36, 2425-37	9.5	430
36	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , <b>2015</b> , 243, 257-9	3.1	123
35	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 109	4.2	20
34	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , <b>2015</b> , 385, 351-61	4.0	409
33	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , <b>2015</b> , 13, 229	11.4	126
32	Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 546-57	7	110
31	New worldwide lipid guidelines. <i>Current Opinion in Cardiology</i> , <b>2015</b> , 30, 447-53	2.1	2

30	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , <b>2015</b> , 11, 1-23	2.9	252
29	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , <b>2015</b> , 36, 1012-22	9.5	770
28	Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated?. <i>Circulation Research</i> , <b>2015</b> , 116, 1646-8	15.7	5
27	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. <i>Atherosclerosis</i> , <b>2015</b> , 241, 62-8	3.1	14
26	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , <b>2015</b> , 241, 433-42	3.1	107
25	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , <b>2014</b> , 35, 960-8	9.5	222
24	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 655-66	18.1	357
23	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , <b>2014</b> , 35, 2146-57	9.5	614
22	Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. <i>Current Opinion in Lipidology</i> , <b>2014</b> , 25, 413-7	4.4	2
21	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1317-26	59.2	2459
20	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , <b>2011</b> , 32, 1345-51	9.5	793
19	Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 2556-64	27.4	944
18	Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 1024-31		277
17	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet</i> , <b>2010</b> , 375, 735-42	4.0	1644
16	Author reply: Which risk engines are best to assess CVD risk in diabetes?. <i>Nature Reviews Endocrinology</i> , <b>2010</b> , 6, 116-116	15.2	
15	Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 30, 10-3	5.1	3
14	Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 424-30	9.4	120
13	Major lipids, apolipoproteins, and risk of vascular disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 1993-2000	27.4	1733

12	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>2009</b> , 373, 1765-72	40	1015
11	Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 724-30	15.1	431
10	Biomarkers, C-reactive proteins and statins in acute coronary syndromes. <i>Fundamental and Clinical Pharmacology</i> , <b>2007</b> , 21 Suppl 2, 31-3	3.1	2
9	Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2007</b> , 9, 46-51	2.1	6
8	Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. <i>Circulation</i> , <b>2007</b> , 115, 3071-8	16.7	111
7	Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 18P-25P	3	52
6	Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. <i>European Heart Journal</i> , <b>2006</b> , 27, 2310-6	9.5	52
5	Intensive statin therapy for treating acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , <b>2006</b> , 15, 1151-9	5.9	3
4	Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1405-10	15.1	243
3	Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1411-6	15.1	252
2	Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1417-24	15.1	99
1	Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. <i>Critical Pathways in Cardiology</i> , <b>2005</b> , 4, 43-5	1.3	8